| 2024-10-07 | -1.45 % |
|
| 2024-10-04 | +0.18 % |
|
| 2024-10-03 | +0.34 % |
|
| 2024-10-02 | +0.08 % |
|
| 2024-10-01 | -1.35 % |
|
| 2024-09-27 | +1.23 % |
|
| 2024-09-25 | -1.39 % |
|
| 2024-09-24 | -1.53 % |
|
| 2024-09-17 | -3.07 % |
|
| 2024-09-13 | +0.57 % |
|
| 2024-08-13 | +1.24 % |
|
| 2024-08-06 | +2.16 % |
|
| 2024-08-02 | -1.67 % |
|
| 2024-07-25 | -31.34 % |
|
| 2024-07-24 | -0.11 % |
|
| 2024-07-23 | -1.07 % |
|
| 2024-07-19 | +0.8 % |
|
| 2024-07-15 | -1.64 % |
|
| 2024-07-11 | -0.99 % |
|
| 2024-07-02 | +1.09 % |
|
| 2024-06-20 | +0.36 % |
- The article discusses recent insider transactions at Edwards Lifesciences, including the sale and acquisition of stock by the CVP of JAPAC, Daniel J. Lippis, the company's strategic business decisions such as selling its Critical Care business, key executive team changes, analyst outlook, financial health, and stock performance improvements leading to a positive outlook, with factors such as revenue growth, market capitalization, and stable stock performance, all contributing to the recent uptick in Edwards Lifesciences' stock.
- The article discusses insider transactions involving the Chief Financial Officer of Edwards Lifesciences Corp (NYSE:EW), Scott B. Ullem, who sold company stock valued at $492,257, but despite this insider selling, the stock of Edwards Lifesciences went up due to positive developments including executive changes, business transactions like the sale of its Critical Care business, analyst upgrades, and a focus on strategic growth initiatives in heart disease innovations, leading to increased investor confidence.
|
| 2024-06-05 | -0.39 % |
|
| 2024-06-03 | +1.12 % |
|
| 2024-05-31 | -1.14 % |
|
| 2024-05-30 | +0.99 % |
|
| 2024-05-22 | -0.14 % |
|
| 2024-05-15 | +4.28 % |
|
| 2024-05-13 | -2.33 % |
|
| 2024-05-09 | +2.74 % |
|
| 2024-05-08 | -0.87 % |
|
| 2024-05-02 | +0.9 % |
|
| 2024-05-01 | -0.44 % |
|
| 2024-04-30 | -1.49 % |
|
| 2024-04-29 | -0.56 % |
|
| 2024-04-26 | -1.8 % |
|
| 2024-04-25 | -0.68 % |
|
| 2024-04-23 | +0.91 % |
|
| 2024-04-22 | +1.19 % |
|
| 2024-04-18 | -0.91 % |
|
| 2024-04-11 | -0.11 % |
- The article discusses how Stratos Wealth Partners LTD. purchased a new position in Edwards Lifesciences Co. (NYSE: EW), with several other hedge funds and institutional investors also modifying their holdings; additionally, some insiders sold company stock recently. Edwards Lifesciences (EW) stock went down possibly due to a combination of factors such as profit-taking after a recent price increase, insider selling, and overall market conditions.
- Summary: Mirae Asset Global Investments Co. Ltd. increased its holdings in Edwards Lifesciences Co., but the stock was down by -0.11% last night, and several hedge funds and institutional investors have added or reduced their stakes in EW. The stock declined likely due to various factors such as investor sentiment, market conditions, or profit-taking by insiders.
Reason for stock decrease: The stock price of Edwards Lifesciences (EW) may have dropped due to general market fluctuations, investor sentiment, or potential profit-taking by insiders, as described in the article.
|
| 2024-04-09 | +0.77 % |
|
| 2024-04-08 | -0.39 % |
|
